The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.

"The guiding principles of good AI practice in drug development are a first step of a renewed EU-US cooperation... to ...

For years, employers have sought to streamline their relationships with drugmakers to lower costs. But until recently, there ...

The U.S. Food and Drug Administration said a comprehensive review “found no increased” risk related to suicide among users of ...

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Strive Compounding Pharmacy, one of the nation's most celebrated providers of compounded medications, has filed a federal antitrust lawsuit against pharmaceutical giants Eli Lilly and Novo Nordisk, ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly and Nvidia are putting up to $1 billion on the table to see whether generative AI can compress the decade-long slog ...

Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...